Man­u­fac­tur­ing roundup: So­ci­etal CD­MO nets new cus­tomers; Chime Bi­o­log­ics gets the OK to man­u­fac­ture an­ti­bod­ies

So­ci­etal CD­MO has been award­ed ser­vice con­tracts for three new cus­tomers. The agree­ments in­clude an ar­ray of man­u­fac­tur­ing ser­vices, for clin­i­cal tri­als, an­a­lyt­i­cal meth­ods, for­mu­la­tion de­vel­op­ment and cGMP man­u­fac­tur­ing.

For the first con­tract, So­ci­etal will sup­port the ini­ti­a­tion of a Phase II clin­i­cal study of an an­ti­de­pres­sant al­ready ap­proved for use in Eu­rope and Aus­tralia. So­ci­etal will be re­spon­si­ble for sourc­ing, prepar­ing, pack­ag­ing and la­bel­ing of both the study drug and match­ing place­bo for use in the tri­al. These ac­tiv­i­ties will be con­duct­ed in col­lab­o­ra­tion at its fa­cil­i­ties in Geor­gia and Cal­i­for­nia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER